These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33387701)

  • 1. Zuranolone as an oral adjunct to treatment of Parkinsonian tremor: A phase 2, open-label study.
    Bullock A; Kaul I; Li S; Silber C; Doherty J; Kanes SJ
    J Neurol Sci; 2021 Feb; 421():117277. PubMed ID: 33387701
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zonisamide effects on sleep problems and depressive symptoms in Parkinson's disease.
    Suzuki K; Fujita H; Matsubara T; Haruyama Y; Kadowaki T; Funakoshi K; Watanabe Y; Hirata K
    Brain Behav; 2021 Mar; 11(3):e02026. PubMed ID: 33399276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Movement disorder society unified Parkinson disease rating scale experiences in daily living: longitudinal changes and correlation with other assessments.
    Lang AE; Eberly S; Goetz CG; Stebbins G; Oakes D; Marek K; Ravina B; Tanner CM; Shoulson I;
    Mov Disord; 2013 Dec; 28(14):1980-6. PubMed ID: 24123383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Zuranolone for the Treatment of Postpartum Depression.
    Deligiannidis KM; Meltzer-Brody S; Maximos B; Peeper EQ; Freeman M; Lasser R; Bullock A; Kotecha M; Li S; Forrestal F; Rana N; Garcia M; Leclair B; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):668-675. PubMed ID: 37491938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA
    Althaus AL; Ackley MA; Belfort GM; Gee SM; Dai J; Nguyen DP; Kazdoba TM; Modgil A; Davies PA; Moss SJ; Salituro FG; Hoffmann E; Hammond RS; Robichaud AJ; Quirk MC; Doherty JJ
    Neuropharmacology; 2020 Dec; 181():108333. PubMed ID: 32976892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zuranolone for the Treatment of Adults With Major Depressive Disorder: A Randomized, Placebo-Controlled Phase 3 Trial.
    Clayton AH; Lasser R; Parikh SV; Iosifescu DV; Jung J; Kotecha M; Forrestal F; Jonas J; Kanes SJ; Doherty J
    Am J Psychiatry; 2023 Sep; 180(9):676-684. PubMed ID: 37132201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Levodopa/carbidopa intestinal gel can improve both motor and non-motor experiences of daily living in Parkinson's disease: An open-label study.
    Juhász A; Aschermann Z; Ács P; Janszky J; Kovács M; Makkos A; Harmat M; Tényi D; Karádi K; Komoly S; Takáts A; Tóth A; Nagy H; Klivényi P; Dibó G; Dézsi L; Zádori D; Annus Á; Vécsei L; Varannai L; Kovács N
    Parkinsonism Relat Disord; 2017 Apr; 37():79-86. PubMed ID: 28185758
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using Movement Disorder Society Unified Parkinson's Disease Rating Scale Parts 2 and 3 Simultaneously: Combining the Patient Voice with Clinician Ratings.
    Guo Y; Goetz CG; Stebbins GT; Mestre TA; Luo S
    Mov Disord; 2023 Mar; 38(3):453-463. PubMed ID: 36621935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zuranolone and its role in treating major depressive disorder: a narrative review.
    Ali M; Ullah I; Diwan MN; Aamir A; Awan HA; Waris Durrani A; Qudrat QU; Shoib S; De Berardis D
    Horm Mol Biol Clin Investig; 2023 Jun; 44(2):229-236. PubMed ID: 36848317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rasagiline treatment effects on parkinsonian tremor.
    Lew MF
    Int J Neurosci; 2013 Dec; 123(12):859-65. PubMed ID: 23767986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, single-dose, cross-over study of the effects of pramipexole, pergolide, and placebo on rest tremor and UPDRS part III in Parkinson's disease.
    Navan P; Findley LJ; Jeffs JA; Pearce RK; Bain PG
    Mov Disord; 2003 Feb; 18(2):176-80. PubMed ID: 12539211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of subcutaneous apomorphine on tremor in idiopathic Parkinson's disease.
    Hellmann MA; Sabach T; Melamed E; Djaldetti R
    Biomed Pharmacother; 2008; 62(4):250-2. PubMed ID: 17967525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Magnetic resonance-guided focused ultrasound thalamotomy for tremor: a report of 30 Parkinson's disease and essential tremor cases.
    Zaaroor M; Sinai A; Goldsher D; Eran A; Nassar M; Schlesinger I
    J Neurosurg; 2018 Jan; 128(1):202-210. PubMed ID: 28298022
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the MDS-UPDRS Part I for nonmotor symptoms in Parkinson's disease.
    Gallagher DA; Goetz CG; Stebbins G; Lees AJ; Schrag A
    Mov Disord; 2012 Jan; 27(1):79-83. PubMed ID: 21915909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting response to dopaminergic treatment for resting tremor of Parkinson's disease.
    Sung YH; Chung SJ; Kim SR; Lee MC
    Mov Disord; 2008 Jan; 23(1):137-40. PubMed ID: 17987649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analyzing the effects of PDSAFEx™ on the motor symptoms of Parkinson's disease: A retrospective study.
    Sangarapillai K; Norman BM; Almeida QJ
    NeuroRehabilitation; 2020; 46(4):589-593. PubMed ID: 32508333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Invasive Transcutaneous Afferent Patterned Stimulation Therapy Offers Action Tremor Relief in Parkinson's Disease.
    Brillman S; Khemani P; Isaacson SH; Pahwa R; Deshpande R; Zraick V; Rajagopal A; Khosla D; Rosenbluth KH
    Tremor Other Hyperkinet Mov (N Y); 2023; 13():25. PubMed ID: 37637850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unilateral thalamic deep brain stimulation for refractory essential tremor and Parkinson's disease tremor.
    Ondo W; Jankovic J; Schwartz K; Almaguer M; Simpson RK
    Neurology; 1998 Oct; 51(4):1063-9. PubMed ID: 9781530
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing the non-motor symptoms of Parkinson's disease: MDS-UPDRS and NMS Scale.
    Martinez-Martin P; Chaudhuri KR; Rojo-Abuin JM; Rodriguez-Blazquez C; Alvarez-Sanchez M; Arakaki T; Bergareche-Yarza A; Chade A; Garretto N; Gershanik O; Kurtis MM; Martinez-Castrillo JC; Mendoza-Rodriguez A; Moore HP; Rodriguez-Violante M; Singer C; Tilley BC; Huang J; Stebbins GT; Goetz CG
    Eur J Neurol; 2015 Jan; 22(1):37-43. PubMed ID: 23607783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rotigotine transdermal system as add-on to oral dopamine agonist in advanced Parkinson's disease: an open-label study.
    Kim JM; Chung SJ; Kim JW; Jeon BS; Singh P; Thierfelder S; Ikeda J; Bauer L;
    BMC Neurol; 2015 Feb; 15():17. PubMed ID: 25879416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.